Analyst Coverage Initiated: ENGN rating Overweight by Morgan Stanley
Price Target: $40
Report Date: 03-08-2024
Symbol: ENGN - enGene Holdings Inc. Common Stock
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Initiated: ENGN rating Overweight by Morgan Stanley
Price Target: $40
enGene Holdings Inc. Common Stock (ENGN)
7171 Rue Frederick Banting
Saint-Laurent, H4S 1Z9
Phone: 514 332 4888
Website: https://www.engene.com
CEO: Mr. Jason D. Hanson Esq., J.D.
NASDAQ, NASDAQ
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
free stock signals, stock market trading signals, best stock signal alert software, free trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228